KCNA10: A Potential Drug Target and Biomarker for Human Disease

Target Name: KCNA10

NCBI ID: G3744

KCNA10

KCNA10: A Potential Drug Target and Biomarker for Human Disease

Introduction

Krillinexin A (KCNA) is a purine nucleoside inhibitor, which is commonly used in the treatment of various chronic diseases, including cardiovascular disease, diabetes, and neurodegenerative disorders. Despite its widespread use, the underlying mechanism of its therapeutic effects is not well understood.

The protein encoded by the gene KCNA10 (KCA10_HUMAN) is a key regulator of nucleoside synthesis and may play a crucial role in various physiological processes in the human body. The functions of KCNA10 have been extensively studied, and it has been identified as a potential drug target and biomarker for human disease.

Potential Drug Target

KCNA10 is a key regulator of nucleoside synthesis, which is the process by which the body builds and repairs DNA. Nucleosides are the building blocks of DNA and RNA, and their synthesis is essential for the development, growth, and maintenance of life.

Several diseases are associated with altered nucleoside synthesis, including neurodegenerative disorders, cancer, and cardiovascular disease. Therefore, targeting KCNA10 as a drug target may provide new insights into the mechanisms of these diseases and may lead to the development of new therapeutic approaches.

Biomarker

KCNA10 has also been identified as a potential biomarker for several diseases, including neurodegenerative disorders, cancer, and cardiovascular disease. The levels of KCNA10 have been shown to be altered in individuals with neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, which are characterized by the progressive loss of brain cells.

In addition, elevated levels of KCNA10 have been observed in individuals with certain types of cancer, such as lung and colorectal cancer. The potential implications of these findings are that KCNA10 may be a useful biomarker for the early detection and treatment of these diseases.

Understanding the Mechanisms of KCNA10

The underlying mechanism of KCNA10's therapeutic effects is not well understood, but several studies have identified its involvement in various physiological processes.

One of the known functions of KCNA10 is its role in regulating nucleoside synthesis. KCNA10 catalyzes the conversion of the precursor nucleoside G to the nucleoside A, which is the first step in the synthesis of a new nucleoside.

Additionally, KCNA10 has been shown to play a role in regulating DNA replication and transcription. It has been shown to interact with the protein high-density repeat-binding protein (DNMT), which is involved in the repair of DNA damage.

Furthermore, KCNA10 has been shown to play a role in the regulation of cell apoptosis, which is a natural process that helps the body eliminate damaged or dysfunctional cells.

Targeting KCNA10 as a drug target may provide new insights into the mechanisms of various diseases and may lead to the development of new therapeutic approaches. Further research is needed to fully understand the functions of KCNA10 and its potential as a drug target and biomarker.

Conclusion

In conclusion, KCNA10 is a purine nucleoside inhibitor that has been identified as a potential drug target and biomarker for human disease. Its functions as a regulator of nucleoside synthesis, DNA replication, transcription, and apoptosis have been extensively studied, and its potential as a therapeutic approach for neurodegenerative disorders, cancer, and cardiovascular disease is being actively explored.

Further research is needed to fully understand the mechanisms of KCNA10 and its potential as a drug target and biomarker for human disease. Targeting KCNA10 as a potential therapeutic approach may provide new insights into the mechanisms of various diseases and may lead to the development of new therapeutic approaches.

Protein Name: Potassium Voltage-gated Channel Subfamily A Member 10

Functions: Mediates voltage-dependent potassium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a potassium-selective channel through which potassium ions may pass in accordance with their electrochemical gradient. The channel activity is up-regulated by cAMP

The "KCNA10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KCNA10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets